-
Intercalated chemotherapy and erlotinib for nonsmall cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutationsZwitter, Matjaž ...Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth ... factor receptor (EGFR), intercalated therapy has not been properly evaluated. In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250 mg/m2, days 1 and 4), cisplatin (75 mg/m2, day 2) and erlotinib (150 mg, days 5 - 15), followed by continuous erlotinib as maintenance. In addition to standard radiologic evaluation according to RECIST, PET/CT was done prior to treatment and at 6 months, using PERCIST as a method for assessment of response. The primary endpoint was progression-free survival (PFS). In general, tolerance to treatment was good, even among 8 patients with performance status 2-3 and 13 patients with brain metastases; grade 4 toxicity included 2 cases of neutropenia and 4 thrombo-embolic events. Complete response (CR) or partial response (PR) were seen in 15 (39.5%) and 17 (44.7%) cases, respectively. All cases of CR were confirmed also by PET/CT. Median PFS was 23.4 months and median overall survival (OS) was 38.3 months. After a median follow-up of 35 months, 8 patients are still in CR and on maintenance erlotinib. In conclusion, intercalated treatment for treatment-naive patients with EGFR activating mutations leads to excellent response rate and prolonged PFS and survival. Comparison of the intercalated schedule to monotherapy with TKIs in a randomized trial is warranted.Source: Cancer biology & therapy. - ISSN 1538-4047 (Vol. 17, iss. 8, 2016, str. 833-839)Type of material - article, component partPublish date - 2016Language - englishCOBISS.SI-ID - 2403451
Author
Zwitter, Matjaž |
Rajer, Mirjana |
Stanič, Karmen, 1964- |
Vrankar, Martina |
Doma, Andrej |
Cuderman, Anka |
Grmek, Marko |
Kern, Izidor |
Kovač, Viljem
Topics
18F-FDG PET/CT |
cisplatin |
EGFR |
NSCLC |
kemoterapija |
nedrobnocelični rak pljuč |
receptor epidermalnega rastnega faktorja |
erlotinib |
cisplatin
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Zwitter, Matjaž | 07750 |
Rajer, Mirjana | 32449 |
Stanič, Karmen, 1964- | 12024 |
Vrankar, Martina | 21746 |
Doma, Andrej | 27933 |
Cuderman, Anka | 39909 |
Grmek, Marko | 11714 |
Kern, Izidor | 15781 |
Kovač, Viljem | 16229 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.